Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient Children

Somatropin (Norditropin) in Children With Growth Failure Associated With ICF Deficiency.

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00102817

Enrollment

149

Registered

2005-02-02

Start date

2003-05-31

Completion date

2006-12-31

Last updated

2017-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Growth Hormone Disorder, Pituitary Dwarfism

Keywords

Growth Hormone Disorder

Brief summary

This trial is conducted in the United States of America (USA). This is a 12 month study to determine if Norditropin is safe and effective in children with IGF deficiency.

Interventions

DRUGsomatropin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

3 Years to 13 Years

Healthy volunteers

Inclusion criteria

* Ages 3-15 * Presence of growth failure indicated by height standard deviation score less than equal to -2 * Body mass index greater than or equal to 25th percentile for height age * IGF concentration less than or equal to 33rd percentile

Design outcomes

Primary

Measure	Time frame
Change in height standard deviation score	12 months

Secondary

Measure	Time frame
12 months change in height standard deviation score adjusted for parent height z-score	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026